Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression–free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

Recent studies suggest CD133, a surface protein widely used for isolation of colon cancer stem cells, to be associated with tumor angiogenesis and recurrence. We hypothesized that gene expression levels and germline variations in CD133 will predict clinical outcome in patients with mCRC, treated in...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Pohl, Alexandra, El-Khoueiry, Anthony, Yang, Dongyun, Zhang, Wu, Lurje, Georg, Ning, Yan, Winder, Thomas, Hu-Lieskoven, Siwen, Iqbal, Sima, Danenberg, Kathleen D., Kahn, Michael, Teo, Jia-Ling, Shriki, Jabi, Stebbing, Justin, Lenz, Heinz-Josef
Format: Artigo
Język:Inglês
Wydane: 2012
Hasła przedmiotowe:
Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3326190/
https://ncbi.nlm.nih.gov/pubmed/22231565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tpj.2011.61
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy